MX2022015074A - Tratamiento antiviral. - Google Patents

Tratamiento antiviral.

Info

Publication number
MX2022015074A
MX2022015074A MX2022015074A MX2022015074A MX2022015074A MX 2022015074 A MX2022015074 A MX 2022015074A MX 2022015074 A MX2022015074 A MX 2022015074A MX 2022015074 A MX2022015074 A MX 2022015074A MX 2022015074 A MX2022015074 A MX 2022015074A
Authority
MX
Mexico
Prior art keywords
azelastine
antiviral
antiviral treatment
treatment
prophylactic
Prior art date
Application number
MX2022015074A
Other languages
English (en)
Spanish (es)
Inventor
Gábor Nagy
Eszter Nagy
Robert Konrat
Valeria Szijarto
Original Assignee
CEBINA GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP20184767.0A external-priority patent/EP3936132A1/en
Application filed by CEBINA GmbH filed Critical CEBINA GmbH
Publication of MX2022015074A publication Critical patent/MX2022015074A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2022015074A 2020-05-29 2021-05-28 Tratamiento antiviral. MX2022015074A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP20177451 2020-05-29
EP20184767.0A EP3936132A1 (en) 2020-07-08 2020-07-08 Azelastine as antiviral treatment
EP20195740 2020-09-11
EP21171333 2021-04-29
PCT/EP2021/064338 WO2021239943A1 (en) 2020-05-29 2021-05-28 Azelastine as antiviral treatment

Publications (1)

Publication Number Publication Date
MX2022015074A true MX2022015074A (es) 2023-02-16

Family

ID=76059910

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022015074A MX2022015074A (es) 2020-05-29 2021-05-28 Tratamiento antiviral.

Country Status (21)

Country Link
US (3) US20230201216A1 (https=)
EP (2) EP3934653B1 (https=)
JP (1) JP2023529025A (https=)
KR (1) KR20230021009A (https=)
CN (1) CN116406273A (https=)
AU (1) AU2021279280A1 (https=)
BR (1) BR112022023897A2 (https=)
CA (1) CA3184167A1 (https=)
DK (1) DK3934653T3 (https=)
ES (1) ES2937145T3 (https=)
FI (1) FI3934653T3 (https=)
HU (1) HUE060929T2 (https=)
IL (1) IL298543A (https=)
JO (1) JOP20220319B1 (https=)
LT (1) LT3934653T (https=)
MX (1) MX2022015074A (https=)
PL (1) PL3934653T3 (https=)
RS (1) RS63940B1 (https=)
SI (1) SI3934653T1 (https=)
SM (1) SMT202300036T1 (https=)
WO (1) WO2021239943A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11806359B2 (en) 2020-03-31 2023-11-07 Phoenix Biotechnology, Inc. Method and compositions for treating Coronavirus infection
ES2937145T3 (es) * 2020-05-29 2023-03-24 CEBINA GmbH Azelastina como tratamiento antiviral

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3877904D1 (de) * 1987-11-13 1993-03-11 Asta Pharma Ag Azelastin enthaltende arzneimittel zur anwendung in der nase und/oder am auge.
DE3836579A1 (de) * 1987-11-13 1989-05-24 Asta Pharma Ag Azelastin enthaltende arzneimittel zur anwendung in der nase und/oder am auge
US20100311656A1 (en) * 2003-04-23 2010-12-09 Sciclone Pharmaceuticals, Inc. Treatment or prevention of respiratory viral infections with alpha thymosin peptides
US8758816B2 (en) * 2004-11-24 2014-06-24 Meda Pharmaceuticals Inc. Compositions comprising azelastine and methods of use thereof
JP2008285474A (ja) 2007-04-17 2008-11-27 Daiichi Sankyo Healthcare Co Ltd 抗アデノウイルス剤を含有する医薬組成物
US8642069B2 (en) * 2008-08-27 2014-02-04 Alexander D. Goldin Composition and method for treating colds
WO2021207213A2 (en) * 2020-04-07 2021-10-14 University Of Florida Research Foundation, Incorporated Methods to prevent sars-cov-2 infection and treat covid-19
US20230142221A1 (en) * 2020-04-10 2023-05-11 Kamal Khan Mubarak Compositions and methods for modulating ace2 receptor
CN113521289A (zh) * 2020-04-16 2021-10-22 中国科学院上海药物研究所 15种药物有效成分在抗病毒感染中的应用
ES2937145T3 (es) * 2020-05-29 2023-03-24 CEBINA GmbH Azelastina como tratamiento antiviral

Also Published As

Publication number Publication date
AU2021279280A1 (en) 2023-01-05
EP3934653A1 (en) 2022-01-12
SMT202300036T1 (it) 2023-03-17
PL3934653T3 (pl) 2023-03-13
US11273163B2 (en) 2022-03-15
EP4190333A1 (en) 2023-06-07
RS63940B1 (sr) 2023-02-28
HUE060929T2 (hu) 2023-04-28
EP3934653B1 (en) 2022-11-09
FI3934653T3 (fi) 2023-03-01
IL298543A (en) 2023-01-01
BR112022023897A2 (pt) 2023-04-04
KR20230021009A (ko) 2023-02-13
ES2937145T3 (es) 2023-03-24
WO2021239943A1 (en) 2021-12-02
SI3934653T1 (sl) 2023-04-28
CN116406273A (zh) 2023-07-07
CA3184167A1 (en) 2021-12-02
JOP20220319B1 (ar) 2024-12-22
JP2023529025A (ja) 2023-07-06
US11433080B2 (en) 2022-09-06
US20230201216A1 (en) 2023-06-29
US20210369730A1 (en) 2021-12-02
LT3934653T (lt) 2023-02-27
DK3934653T3 (da) 2023-02-13
US20220143040A1 (en) 2022-05-12

Similar Documents

Publication Publication Date Title
NZ775660A (en) Combination therapy including a krasg12c inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
PH12016502355B1 (en) Pharmaceutical composition
ZA202202361B (en) Treatment of hidradenitis suppurativa using jak inhibitors
GEAP202315703A (en) Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer
PH12018501001A1 (en) Therapeutic compositions for treatment of human immunodeficiency virus
MX2020008258A (es) Formulaciones pediátricas de niraparib y métodos de tratamiento pediátricos.
MX2020004023A (es) Uso de un inhibidor de pcsk9 para tratar la hiperlipidemia.
WO2016133903A3 (en) Combination therapy for cancer treatment
PH12016502353A1 (en) Pharmaceutical composition
RU2017120184A (ru) Лекарства для замедления течения болезни паркинсона
MX2021006884A (es) Compuestos y su uso para el tratamiento de la deficiencia de alfa1-antitripsina.
MY202884A (en) Compounds useful in hiv therapy
ZA201607489B (en) Combination comprising a glucocorticoid and edo-s101
PH12020500099A1 (en) Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a cyclin d kinase inhibitor
MA39765A (fr) Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation
PH12020550462A1 (en) Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same
JOP20200014A1 (ar) توليفة علاجية لمثبط كيناز تيروزين egfr من الجيل الثالث ومثبط raf
MX2022000390A (es) Derivados macrociclicos espirociclicos como inhibidores de mcl-1.
JOP20220319B1 (ar) أزيلاستين كعلاج مضاد للفيروسات
PH12020500542A1 (en) Dopamine-b-hydroxylase inhibitors
ZA201906153B (en) Pharmaceutical compositions for combination therapy
PL423672A1 (pl) Kompozycja farmaceutyczna zawierająca zebularynę oraz środek leczniczy do regeneracji ran
EA202190317A1 (ru) Лекарственный препарат для наружного применения
IN2014MN01546A (https=)
EA201990553A1 (ru) Применение придопидина для лечения ухудшения функциональной способности